288 related articles for article (PubMed ID: 12358740)
1. Increased vulnerability of dopaminergic neurons in MPTP-lesioned interleukin-6 deficient mice.
Bolin LM; Strycharska-Orczyk I; Murray R; Langston JW; Di Monte D
J Neurochem; 2002 Oct; 83(1):167-75. PubMed ID: 12358740
[TBL] [Abstract][Full Text] [Related]
2. Neuroprotection in Parkinson models varies with toxin administration protocol.
Anderson DW; Bradbury KA; Schneider JS
Eur J Neurosci; 2006 Dec; 24(11):3174-82. PubMed ID: 17156378
[TBL] [Abstract][Full Text] [Related]
3. Regulation of dopaminergic loss by Fas in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
Hayley S; Crocker SJ; Smith PD; Shree T; Jackson-Lewis V; Przedborski S; Mount M; Slack R; Anisman H; Park DS
J Neurosci; 2004 Feb; 24(8):2045-53. PubMed ID: 14985447
[TBL] [Abstract][Full Text] [Related]
4. Riluzole (2-amino-6-trifluoromethoxy benzothiazole) attenuates MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) neurotoxicity in mice.
Araki T; Muramatsu Y; Tanaka K; Matsubara M; Imai Y
Neurosci Lett; 2001 Oct; 312(1):50-4. PubMed ID: 11578843
[TBL] [Abstract][Full Text] [Related]
5. Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease.
Breidert T; Callebert J; Heneka MT; Landreth G; Launay JM; Hirsch EC
J Neurochem; 2002 Aug; 82(3):615-24. PubMed ID: 12153485
[TBL] [Abstract][Full Text] [Related]
6. Compromised reactive microgliosis in MPTP-lesioned IL-6 KO mice.
Cardenas H; Bolin LM
Brain Res; 2003 Sep; 985(1):89-97. PubMed ID: 12957371
[TBL] [Abstract][Full Text] [Related]
7. Single low doses of MPTP decrease tyrosine hydroxylase expression in the absence of overt neuron loss.
Alam G; Edler M; Burchfield S; Richardson JR
Neurotoxicology; 2017 May; 60():99-106. PubMed ID: 28377118
[TBL] [Abstract][Full Text] [Related]
8. Evidence for a protective action of the vigilance promoting drug modafinil on the MPTP-induced degeneration of the nigrostriatal dopamine neurons in the black mouse: an immunocytochemical and biochemical analysis.
Fuxe K; Janson AM; Rosén L; Finnman UB; Tanganelli S; Morari M; Goldstein M; Agnati LF
Exp Brain Res; 1992; 88(1):117-30. PubMed ID: 1347270
[TBL] [Abstract][Full Text] [Related]
9. EGb761 protects against nigrostriatal dopaminergic neurotoxicity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinsonism in mice: role of oxidative stress.
Rojas P; Serrano-García N; Mares-Sámano JJ; Medina-Campos ON; Pedraza-Chaverri J; Ogren SO
Eur J Neurosci; 2008 Jul; 28(1):41-50. PubMed ID: 18662333
[TBL] [Abstract][Full Text] [Related]
10. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
[TBL] [Abstract][Full Text] [Related]
11. CX3CR1 Disruption Differentially Influences Dopaminergic Neuron Degeneration in Parkinsonian Mice Depending on the Neurotoxin and Route of Administration.
Tristão FS; Lazzarini M; Martin S; Amar M; Stühmer W; Kirchhoff F; Gomes LA; Lanfumey L; Prediger RD; Sepulveda JE; Del-Bel EA; Raisman-Vozari R
Neurotox Res; 2016 Apr; 29(3):364-80. PubMed ID: 26403659
[TBL] [Abstract][Full Text] [Related]
12. Pattern of levodopa-induced striatal changes is different in normal and MPTP-lesioned mice.
Gross CE; Ravenscroft P; Dovero S; Jaber M; Bioulac B; Bezard E
J Neurochem; 2003 Mar; 84(6):1246-55. PubMed ID: 12614325
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-18 null mice show diminished microglial activation and reduced dopaminergic neuron loss following acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment.
Sugama S; Wirz SA; Barr AM; Conti B; Bartfai T; Shibasaki T
Neuroscience; 2004; 128(2):451-8. PubMed ID: 15350655
[TBL] [Abstract][Full Text] [Related]
14. Damage to the nigrostriatal system in the MPTP-treated SAMP8 mouse.
Liu J; Wang YY; Liu L; Wang QD; Yuan ZY; Zhang ZX; Gu P; Wang MW
Neurosci Lett; 2008 Dec; 448(2):184-8. PubMed ID: 18977411
[TBL] [Abstract][Full Text] [Related]
15. The role of the MYD88-dependent pathway in MPTP-induced brain dopaminergic degeneration.
Drouin-Ouellet J; Gibrat C; Bousquet M; Calon F; Kriz J; Cicchetti F
J Neuroinflammation; 2011 Oct; 8():137. PubMed ID: 21989292
[TBL] [Abstract][Full Text] [Related]
16. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease.
Wu DC; Jackson-Lewis V; Vila M; Tieu K; Teismann P; Vadseth C; Choi DK; Ischiropoulos H; Przedborski S
J Neurosci; 2002 Mar; 22(5):1763-71. PubMed ID: 11880505
[TBL] [Abstract][Full Text] [Related]
17. Regional and temporal expression of the peripheral benzodiazepine receptor in MPTP neurotoxicity.
Kuhlmann AC; Guilarte TR
Toxicol Sci; 1999 Mar; 48(1):107-16. PubMed ID: 10330690
[TBL] [Abstract][Full Text] [Related]
18. Role of nitric oxide synthase against MPTP neurotoxicity in mice.
Kurosaki R; Muramatsu Y; Michimata M; Matsubara M; Kato H; Imai Y; Itoyama Y; Araki T
Neurol Res; 2002 Oct; 24(7):655-62. PubMed ID: 12392201
[TBL] [Abstract][Full Text] [Related]
19. Cellular distribution of interleukin-1alpha-immunoreactivity after MPTP intoxication in mice.
Hébert G; Mingam R; Arsaut J; Dantzer R; Demotes-Mainard J
Brain Res Mol Brain Res; 2005 Aug; 138(2):156-63. PubMed ID: 15922486
[TBL] [Abstract][Full Text] [Related]
20. Age-related severity of dopaminergic neurodegeneration to MPTP neurotoxicity causes motor dysfunction in C57BL/6 mice.
Ohashi S; Mori A; Kurihara N; Mitsumoto Y; Nakai M
Neurosci Lett; 2006 Jun; 401(1-2):183-7. PubMed ID: 16581184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]